和肽素单独或联合肌钙蛋白早期排除非ST段抬高型心肌梗死的性别差异
该研究在852例因胸痛疑似NSTEMI就诊于急诊科的成人中测量生物标志物,其中女性362例(42.5%)、男性490例(57.5%)。男性和肽素中位数高于女性(7.36 pmol/L vs 4.8 pmol/L,P<.001)。双标志物排除策略的阴性预测值在男性为100%、女性为99.6%(CI 98.8-100),与单用肌钙蛋白相比(男女均为98.7%)表现相似。多因素逻辑回归显示男性与和肽素升高正相关(OR=2.37),且和肽素升高的预测因素存在性别特异性。
要点
- 双标志物(和肽素+肌钙蛋白)排除策略在男性中阴性预测值为100%,女性为99.6%(CI 98.8-100),两性表现相似。
- 男性和肽素水平中位数7.36 pmol/L,高于女性的4.8 pmol/L(P<.001)。
- 男性性别与和肽素升高独立正相关(OR=2.37,95%CI 1.61-3.49,P<.001)。
- 男性中和肽素升高的预测因素包括当前心肌梗死(OR=2.16)、慢性肾功能不全(OR=3.58)、心房颤动(OR=2.56),舒张压为负向预测因素(OR=0.98)。
- 女性中和肽素升高的预测因素包括当前心肌梗死(OR=2.98)、心房颤动(OR=2.90)和晕厥样事件(OR=7.56)。
适用人群与场景
- 因胸痛疑似非ST段抬高型心肌梗死就诊于急诊科的成人患者,共852例(女性362例,男性490例)。
研究设计与关键结果
- 研究类型为在急诊科就诊的疑似NSTEMI成人中测量生物标志物的研究,样本量852例(女性362例,男性490例)。
- 双标志物排除策略的阴性预测值:男性100%,女性99.6%(CI 98.8-100);单用肌钙蛋白的阴性预测值:男性98.7%(CI 97.5-99.8),女性98.7%(CI 97.5-100)。
- 男性与和肽素升高正相关(OR=2.37,95%CI 1.61-3.49,P<.001)。
- 男性中和肽素升高的预测因素:当前心肌梗死OR=2.16(95%CI 1.19-3.91),慢性肾功能不全OR=3.58(95%CI 1.33-9.62),心房颤动OR=2.56(95%CI 1.23-5.32),舒张压OR=0.98(95%CI 0.96-0.99)。
- 女性中和肽素升高的预测因素:当前心肌梗死OR=2.98(95%CI 1.23-7.24),心房颤动OR=2.90(95%CI 1.26-6.70),晕厥样事件OR=7.56(95%CI 2.26-25.30)。
证据类型、等级与局限
- 证据类型为在急诊科就诊的疑似NSTEMI成人中测量生物标志物的研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于疑似NSTEMI的男性和女性患者,和肽素联合肌钙蛋白的双标志物排除策略具有相似的阴性预测值,可用于早期排除。
- 男性患者和肽素水平较高,在解读和肽素结果时需考虑性别差异。
- 和肽素升高的预测因素存在性别差异:男性中慢性肾功能不全、心房颤动、当前心肌梗死和舒张压与和肽素升高相关;女性中当前心肌梗死、心房颤动和晕厥样事件与和肽素升高相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Little is known about the role of gender in the dual biomarker strategy using copeptin and troponin for the early rule-out of non-ST-elevation myocardial infarction (NSTEMI). We aimed to evaluate gender-based differences on copeptin levels, combined negative predictive value (NPV) and predictors of copeptin elevation at admission.
METHODS: Biomarkers were measured in 852 adult patients presenting to the emergency department with chest pain and suspected NSTEMI. Logistic regression analyses on predictors of copeptin elevation were evaluated by gender.
RESULTS: Overall, 362 women (42.5%) and 490 men (57.5%) were included. Copeptin levels were higher in men (median 7.36 pmol/L vs. 4.8 pmol/L; P < .001). Men had a similar NPV (100%) as women (99.6%, CI: 98.8-100) using the dual biomarker rule-out strategy and when compared to troponin alone (men, NPV = 98.7%, CI: 97.5-99.8; and women, NPV = 98.7%, CI: 97.5-100). Multivariate logistic regression showed positive association of male gender with copeptin elevation (OR = 2.37; CI: 1.61-3.49; P < .001). In men, diastolic blood pressure was a negative predictor of copeptin elevation (OR = 0.98, 95% CI: 0.96-0.99), while positive predictors were current MI (OR = 2.16, 95% CI: 1.19-3.91), chronic renal insufficiency (OR = 3.58, 95% CI: 1.33-9.62), and atrial fibrillation (OR = 2.56, 95% CI: 1.23-5.32), respectively (all P < .05). In women, current MI (OR = 2.98, CI: 1.23-7.24), atrial fibrillation (OR = 2.90, CI: 1.26-6.70) and syncope-like events (OR = 7.56, CI: 2.26-25.30) were significant predictors of copeptin elevation.
CONCLUSIONS: Men with suspected NSTEMI have higher copeptin levels. The dual biomarker rule-out strategy has a similar performance in both male and female patients. Certain predictors of copeptin elevation are gender-specific.
参考来源
- Vargas KG, Tajsic M, Latsuzbaia A, et al. Gender-based differences of copeptin alone or combined with troponin for early rule-out of non-ST-elevation myocardial infarction. Am J Emerg Med. 2020. PMID: 33041108. doi:10.1016/j.ajem.2020.08.053
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。